(lp0
S'Company Update : Merrimack Pharmaceuticals Inc Announces 4Q and ... Smarter Analyst - Mar 1, 2017 Merrimack Pharmaceuticals, Inc. engages in discovering, developing and preparing to commercialize innovative medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer.Merrimack Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 01 - Equities.comMerrimack Pharmaceuticals Inc.: Merrimack Reports Fourth Quarter and Full-Year ... - The Wall Street Transcript'
p1
aS"Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 Motley Fool - Jan 9, 2017 While 2016 was a rough period for the biotech industry in general, shareholders of Merrimack Pharmaceuticals  had to suffer through an especially brutal period.Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and ... - PR Newswire Merrimack Pharmaceuticals Inc  Stock Soars on Ipsen Deal - Investorplace.com"
p2
aS'Why Merrimack Pharmaceuticals Inc Fell 20.3% in August Motley Fool - Sep 12, 2016 Shares of Merrimack Pharmaceuticals , a commercial-stage oncology company, plunged more than 20% in August according to data from S&amp;P Global Market Intelligence.'
p3
aS'Earnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through ... Nasdaq - Mar 1, 2017 Merrimack Pharmaceuticals Inc  is due to issue its quarterly earnings report in the upcoming extended-hours session.'
p4
aS"Merrimack Pharmaceuticals Inc  Sees Large Growth in Short Interest Chaffey Breeze - 23 hours ago Merrimack Pharmaceuticals logo Merrimack Pharmaceuticals Inc  was the target of a significant increase in short interest in the month of February.Sell-side is Weighing in on Merrimack Pharmaceuticals, Inc.  Earnings - Aiken AdvocateMerrimack Pharmaceuticals, Inc.'s  stock price is now at $3.11 Analysts ... - Hot Stocks Point"
p5
aS"Merrimack Pharmaceuticals Inc.  Plunges 5.26% on March 07 Equities.com - Mar 7, 2017 Merrimack Pharmaceuticals Inc.  had a rough trading day for Tuesday March 07 as shares tumbled 5.26%, or a loss of $-0.17 per share, to close at $3.06.Merrimack Pharmaceuticals Inc  Receives Consensus Recommendation of Buy ... - Chaffey BreezeMerrimack Pharmaceuticals, Inc.'s  stock price is Currently Worth at $3.23 - Hot Stocks Point"
p6
aS'Merrimack Pharmaceuticals Inc.: Merrimack Announces Timing of Fourth Quarter ... The Wall Street Transcript - Feb 22, 2017 CAMBRIDGE, Mass., Feb. 22, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.  today announced that the company will host its Fourth Quarter 2016 investor conference call and webcast at 8:30 a.m.Merrimack Pharmaceuticals, Inc.  Scheduled to Post Earnings on Thursday - The Cerbat GemHot Stock Update: Merrimack Pharmaceuticals, Inc.  - HugoPress'
p7
aS"Latest Updates :Merrimack Pharmaceuticals, Inc.'s  stock price is Worth ... Hot Stocks Point - Mar 13, 2017 Merrimack Pharmaceuticals, Inc.  stock price ended its day with gain 1.94% and finalized at the price of $3.15.Analyst's Report on: Merrimack Pharmaceuticals Inc  - Post RegistrarThe Way Wall Street Experts See Merrimack Pharmaceuticals, Inc.  - Post Analyst"
p8
aS'Equity Review: Looking Closer at Shares of Merrimack Pharmaceuticals, Inc ... SKV News - 12 hours ago Taking a closer look at some quality ratios for Merrimack Pharmaceuticals, Inc. , the firm has a Gross Margin  ratio of -0.254728.'
p9
aS'Looking Mainly At Fundamentals: PDL BioPharma, Inc. , Merrimack ... USA Commerce Daily - 22 hours ago Shares of PDL BioPharma, Inc.  observed rebound of 10.36% since bottoming out at $1.93 on Dec. 20, 2016. Thanks to a rise of almost 1.91% in the past five days, the stock price is now up 0.47% so far on the year - still in weak territory.Biotech news that matter for investors: PDL BioPharma, Inc. (NASDAQ:PDLI ... - The Voice Registrar'
p10
a.